In one scenario, a sterilizing cure – the complete eradication of all replication-competent HIV in an organism – has most likely been achieved; however, this scenario will be difficult to reproduce and impossible to scale with current technology. Current HIV-related work is thus mainly based on obtaining a long-term effective cure, or 'remission.' For a specified time (to be established yet) without antiretroviral therapy (ART), and without either CD4 + T-cell loss or HIV symptoms or the potential for HIV transmission, we describe remission as undetectable viremia. Risks to active research participants in the field of recovery come from toxicity and invasive medical tests, as well as ATI. Secondly, many of the medications currently being developed for HIV reversal have been found toxic. This is accentuated by growing appreciation of the direct implications of rapidly emerging advances in cancer immunotherapy for achieving an HIV remission. Many treatments aimed at improving the immune response in cancer and possibly in HIV (either for a sterilizing cure or for remission) include the use of gene-modified T cells and gene-editing approaches; known and unknown toxicity is also a major concern for these. Far less common in research ethics tackles risk from trials to non-participating people, but there are some approaches. For example, in HIV remission studies with an ATI that placed sexual partners of participants at risk of transmission, research procedures may include advice on safe sex practices or pre-exposure prophylaxis for healthy study partners. Many research aim to reduce risk by selecting low-risk participants [e.g. , in the case of ATI remission trials, except applicants with a history of Clinical Events of Category C disease control and prevention centers (1993) or those with Kaposi's cutaneous sarcoma. To ensure that risks in HIV remission studies and cure-related research in general are justified to all parties, it remains important to ensure that these studies serve a very urgent social function which justifies placing some individuals at serious risks as is often unavoidable in this undertaking. Leading anti-utilitarian ethicists have been of the opinion that great importance for the health of other people may also be almost sufficient to justify this. This review tells about the future scope of the new invention towards the field of HIV /AIDS and their medicinal treatment. People who are interested can send their article towards our journal for publication through this https://www.scholarscentral.org/submissions/hiv-aids-research.html